Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245268 | 0.86 | LMNA (0.50) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL6209009 | 0.86 | LMNA (0.50) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL6209012 | 0.86 | LMNA (0.50) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL10245473 | 0.82 | TSHR (0.39) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL10246425 | 0.82 | TSHR (0.39) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL23961591 | 0.82 | TSHR (0.36) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL7750990 | 0.82 | TSHR (0.36) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL13761806 | 0.82 | TSHR (0.36) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL10246446 | 0.82 | TSHR (0.39) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL14266749 | 0.82 | LMNA (0.36) | LMNATDP1CNR1ADRA1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986158-A | Substituted biphenyl compound, preparation method and application | 云南大学 | 2024-05-07 | — | — | CN | disclosed |
| US-11773065-B2 | Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| CN-111757935-A | Bivalent nucleic acid ligand and use thereof | 卡耐基梅隆大学 | 2020-10-09 | — | — | CN | disclosed |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-03-03 | — | — | US | disclosed |
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-10314816-B2 | Antimicrobial compounds, compositions and methods of use thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
| US-10220026-B2 | Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer | THE UNIVERSITY OF TOKYO (JP) | 2019-03-05 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | LMNA 1681/4885TDP1 4641/4885CNR1 31/4885 |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | ABCG2, CYP3A43, CYP2D6 | LMNA 2475/4885TDP1 1847/4885CNR1 1119/4885 |
| US-10314816-B2 | Antimicrobial compounds, compositions and methods of use thereof | CLPP, ATP5ME, PCNA | LMNA 2044/4885TDP1 3579/4885CNR1 4123/4885 |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | CYP2F1, CYP4B1, CYP3A4 | LMNA 539/4885TDP1 3015/4885CNR1 1803/4885 |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | LTB4R, LTC4S, LTA4H | LMNA 3805/4885TDP1 1733/4885CNR1 895/4885 |
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | CYP3A7, CYP2A7, CYP2J2 | LMNA 1942/4885TDP1 3017/4885CNR1 33/4885 |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | LMNA 2527/4885TDP1 3955/4885CNR1 411/4885 |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | LMNA 4150/4885TDP1 1225/4885CNR1 1479/4885 |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | GALE, UGGT1, UGT1A3 | LMNA 1273/4885TDP1 2448/4885CNR1 1824/4885 |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | S1PR1, S1PR2, S1PR3 | LMNA 1365/4885TDP1 928/4885CNR1 57/4885 |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | LMNA 3168/4885TDP1 4011/4885CNR1 100/4885 |
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | CYP3A7, UGT2B7, BDKRB1 | LMNA 2390/4885TDP1 3381/4885CNR1 38/4885 |
| US-10220026-B2 | Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer | ABCC1, ABCB1, TOP2A | LMNA 1646/4885TDP1 2662/4885CNR1 3121/4885 |
| US-11773065-B2 | Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists | GPR52, GPR68, GPR65 | LMNA 4441/4885TDP1 4390/4885CNR1 48/4885 |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | CSNK1A1, PRKX, PRKACA | LMNA 2484/4885TDP1 1171/4885CNR1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.